Fig. 2From: Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recoveryCumulative incidence of neutrophil engraftment and platelet engraftment. Left panel: cumulative incidence of neutrophil engraftment in plerixafor-treated patients (solid line) and control patients (dashed line). Right panel: cumulative incidence of platelet engraftment in plerixafor-treated patients (solid line) and contemporaneous control patients (dashed line). Excluding the two bone marrow recipientsBack to article page